<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01754246</url>
  </required_header>
  <id_info>
    <org_study_id>CYN12-PICO-PLASIAN</org_study_id>
    <nct_id>NCT01754246</nct_id>
  </id_info>
  <brief_title>Evaluation of the 755nm Alexandrite Laser for Skin Toning and Epidermal Pigmented Lesions in Asian Skin Types</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cynosure, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cynosure, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess treatment for facial skin toning and removal of
      epidermal pigmented lesions for Asian patients using the 755nm Alexandrite laser
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Photographic Evaluation</measure>
    <time_frame>up to 4 months post last treatment</time_frame>
    <description>2D Photography to assess progress pre and post treatment</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Epidermal Pigmented Lesions</condition>
  <condition>Skin Toning</condition>
  <arm_group>
    <arm_group_label>Alexandrite Laser for Skin Toning</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>755 nm Alexandrite Laser for Skin Toning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alexandrite Laser for Pigmented Lesions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>755nm Alexandrite Laser for Epidermal Pigmented Lesions</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>755nm Alexandrite Laser</intervention_name>
    <description>755nm Alexandrite laser for treatment of epidermal pigmented lesions and skin toning in Asian skin types</description>
    <arm_group_label>Alexandrite Laser for Skin Toning</arm_group_label>
    <arm_group_label>Alexandrite Laser for Pigmented Lesions</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Is a healthy male or female between 18 and 85 years old

          2. Has unwanted facial epidermal pigmented lesions or desires facial skin toning and
             wishes to undergo laser treatments.

          3. Is willing to consent to participate in the study.

          4. Is willing to comply with all requirements of the study including being photographed,
             following post treatment care and attending all treatment and follow up visits.

          5. Has Fitzpatrick skin types III to IV.

        Exclusion Criteria:

          1. The subject is female and pregnant, has been pregnant within the last 3 months, is
             currently breast feeding or planning a pregnancy during the study period.

          2. The subject is hypersensitive to light exposure OR takes photo sensitized medication.

          3. The subject has active or localized systemic infections

          4. The subject has a coagulation disorder, or is currently using anti-coagulation
             medication (including but not limited to heavy aspirin therapy {greater than 81 mg per
             day}).

          5. The subject has any condition which, in the investigator's opinion, would make it
             unsafe for the subject to participate in this research study.

          6. The subject is currently enrolled in an investigational drug or device trial, or has
             received an investigational drug or been treated with an investigational device within
             3 months prior to entering this study.

          7. The subject has used Accutane within 6 months prior to enrollment.

          8. The subject has the need to be exposed to artificial tanning devices or excessive
             sunlight during the trial.

          9. The subject has had prior treatment with parenteral gold therapy (gold sodium
             thiomalate).

         10. The subject has a history of keloids or hypertrophic scarring.

         11. The subject has evidence of compromised wound healing.

         12. The subject has a history of squamous cell carcinoma or melanoma

         13. The subject has a history of immunosuppression/immune deficiency disorders (including
             HIV infection or AIDS) or use of immunosuppressive medications.

         14. Allergic to topical lidocaine or topical steroids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia Krantz</last_name>
    <role>Study Director</role>
    <affiliation>Cynosure, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Skin Care Physicians</name>
      <address>
        <city>Chestnut Hill</city>
        <state>Massachusetts</state>
        <zip>02467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2012</study_first_submitted>
  <study_first_submitted_qc>December 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2012</study_first_posted>
  <last_update_submitted>July 29, 2015</last_update_submitted>
  <last_update_submitted_qc>July 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

